Cargando…
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer
Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova‐T) is an antibody‐drug conjugate that targets delta‐like 3 on SCLC cells to deliver a cytotoxic payload directly to tumor cells. In this study, the cardiac safety pro...
Autores principales: | Goldman, Jonathan W., Barve, Minal, Patel, Jyoti D., Wozniak, Antoinette, Dowlati, Afshin, Starodub, Alexander, Owonikoko, Taofeek K., Edenfield, William, Laurie, Scott A., Da Costa, Daniel, Lally, Satwant, Koch, Martina, Kosloski, Matthew P., Hoffman, David, Dy, Grace K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993269/ https://www.ncbi.nlm.nih.gov/pubmed/33340277 http://dx.doi.org/10.1111/cts.12928 |
Ejemplares similares
-
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
por: Lindner, Daniel J., et al.
Publicado: (2020) -
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
por: Lashari, Bilal H., et al.
Publicado: (2018) -
Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma
por: Krytska, Kateryna, et al.
Publicado: (2022) -
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
por: Mansfield, Aaron S., et al.
Publicado: (2021) -
Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity
por: Ataee, Mohammad Hossein, et al.
Publicado: (2022)